Tech
FDA-cleared exoskeleton puts spinal-cord patients back on their feet
Publication: New Atlas: Technology-Innovation-Outdoor News
Author: Omar Kardoudi
Source published: 27/09/2026, 08:03:00 UTC
Briefing created: 27/09/2026, 08:14:19 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 27/09/2026, 08:13:24 UTC.
Briefings
The US Food and Drug Administration (FDA) has authorized commercial sale of Eve, a personal exoskeleton developed by French company Wandercraft, marking a major milestone for spinal-cord injury patients. This approval follows the device clearing its biggest hurdle, allowing individuals with spinal cord injuries to stand up, interact socially, and perform daily tasks like cooking without assistance. The device represents a significant advancement in wearable robotics for mobility support.
Key points
- The US Food and Drug Administration (FDA) authorized commercial sale of Eve, a personal exoskeleton developed by French company Wandercraft, allowing spinal-cord injury patients to stand, interact socially, and cook without assistance.
- Eve cleared its biggest hurdle by obtaining FDA clearance, enabling users to perform complex daily activities such as standing upright and stirring a pot on a stove independently.
Context and limitations
This briefing covers the FDA's authorization for Eve's commercial sale and its primary capabilities. It does not include details on the device's specific weight, battery life, or clinical trial results. Coverage is limited to the regulatory approval and its immediate functional implications for users.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 27/09/2026, 08:14:19 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeiadiv3tidg3jrhkglvgs2k7bwdiw33kbxfrqwrytx7ckoy7mlifha